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Management of acute upper gastrointestinal 
bleeding: an update for the general physician
K Siau1, W Chapman2, N Sharma3, D Tripathi4, T Iqbal5, N Bhala6
Acute upper gastrointestinal bleed (AUGIB) is one of the most common 
medical emergencies in the UK, with roughly one presentation every 6 min. 
Despite advances in therapeutics and endoscopy provision, mortality following 
AUGIB over the last two decades has remained high, with over 9,000 deaths 
annually in the UK; consequently, several national bodies have published UK-
relevant guidelines. Despite this, the 2015 UK National Con dential Enquiry 
into Patient Outcome and Death in AUGIB highlighted variations in practice, raised concerns 
regarding suboptimal patient care and released a series of recommendations. This review 
paper incorporates the latest available evidence and UK-relevant guidelines to summarise 
the optimal pre-endoscopic, endoscopic, and post-endoscopic approach to and management 
of non-variceal and variceal AUGIB that will be of practical value to both general physicians 
and gastroenterologists.
Keywords: gastrointestinal bleed, haemorrhage, non-variceal, upper gastrointestinal 
bleeding, variceal
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Abstract
Introduction 
Acute upper gastrointestinal bleed (AUGIB) is one of the 
most common medical emergencies in the UK, with an 
estimated incidence of 134 per 100,000,1 roughly equating 
to one presentation every 6 min.2 Despite advances in 
therapeutics and endoscopy provision, mortality following 
AUGIB over the last two decades has remained high, with 
over 9,000 deaths annually in the UK.3
The ﬁ rst UK audit of AUGIB in 1993 reported an overall 
mortality of 14% (11% in patients admitted with AUGIB, 
and 33% of inpatients who develop AUGIB).4 A follow-up 
national audit in 2007 demonstrated a mortality of 10% 
(7% in patients admitted with AUGIB, and 26% of inpatient 
bleeds).5 Consequently, UK-relevant guidelines have been 
published by the National Institute for Health and Care 
Excellence (NICE),6 the Scottish Intercollegiate Guidelines 
Network (SIGN) in conjunction with the British Society of 
Gastroenterology (BSG)7 and, more recently, the European 
Society of Gastrointestinal Endoscopy (ESGE).8 Despite 
this, the 2015 National Conﬁ dential Enquiry into Patient 
Outcome and Death (NCEPOD) of UK patients with AUGIB 
highlighted variations in practice and raised concerns 
regarding suboptimal patient care, releasing a series of 
recommendations.2
Diagnosis 
Deﬁ ned anatomically as bleeding in the upper gastrointestinal 
tract proximal to the ligament of Treitz,7 AUGIB should be 
suspected in patients with haematemesis, coffee-ground 
vomiting, melaena or unexplained fall in haemoglobin. In up 
to 20% of cases, AUGIB may mimic lower gastrointestinal 
bleeding.9 Features that predict AUGIB in cases of 
haematochezia include haemodynamic instability, increased 
serum urea:creatinine ratio, and reduced haematocrit.9 The 
diagnosis is conﬁ rmed with endoscopy, which also serves 
to provide a therapeutic intervention. Based on endoscopic 
diagnoses from the 2007 audit,5 the aetiologies of AUGIB 
are summarised in Figure 1. 
Pragmatically, AUGIB can be divided into variceal and non-
variceal UGIB (NVUGIB) causes, as there are important 
differences in management strategies. The proportion of 
variceal bleeding has doubled from 4% in the 1994 audit,4 
to 8% in 2007,5 correlating with the increasing burden of 
liver disease. Peptic ulcer disease (PUD) remains the most 
common cause of AUGIB, despite reductions in PUD incidence 
and mortality over the last three decades.10 These reductions 
are largely attributable to developments in proton pump 
inhibitors (PPI), endotherapy, Helicobacter pylori eradication, 
and reductions in use of non-steroidal anti-inﬂ ammatory 
drugs (NSAIDs).
1Gastroenterology Registrar and JAG National Clinical Fellow, Department of Gastroenterology, Russell’s Hall Hospital, Dudley; 2Lead Nurse 
Endoscopist, 5,6Consultant Gastroenterologist, Department of Gastroenterology, University Hospital Birmingham, Birmingham; 3Consultant 
Gastroenterologist, Heartlands Hospital, Birmingham; 4Consultant Hepatologist, Liver Unit, University Hospital Birmingham, UK
Correspondence to: 
N Bhala
Department of 
Gastroenterology
University Hospital 
Birmingham
Mindelsohn Way
Birmingham B15 2TH
UK
 
Email: 
neeraj.bhala@uhb.nhs.uk
JOURNAL OF THE ROYAL COLLEGE OF PHYSICIANS OF EDINBURGH  VOLUME 47  ISSUE 3  SEPTEMBER 2017    219 
Management of acute upper GI bleeding: an update
Pre-endoscopic management
1. Assessment and resuscitation
All patients with AUGIB should be promptly assessed and 
triaged for early fluid/blood product resuscitation and 
endoscopy.7 In the unstable patient, early assistance from 
the intensive care team should be considered, especially in the 
case of airway compromise from haematemesis, hypoxia, or in 
cases of reduced level of consciousness from decompensated 
liver disease. The priority should be to ensure a safe airway, 
secure intravenous access for ﬂ uid resuscitation (at least 
two 16–18G intravenous cannulae), and pre-endoscopic 
optimisation.7 Intraosseous access may be an early alternative 
to central venous cannulation if peripheral cannulation fails. 
Standard blood tests including clotting and a crossmatch 
should be urgently performed. Blood gas sampling may 
provide a rapid haemoglobin estimate and indicate acid-base 
disturbances and hyperlactataemia which may occur with tissue 
hypoperfusion. In the event of catastrophic haemorrhage, most 
hospitals in the UK have implemented switchboard-activated 
major haemorrhage protocols in line with national standards,11 
which expedites Group O-negative blood, platelets, and fresh 
frozen plasma, in addition to alerting key clinical and support 
personnel.11 The duty endoscopist should be notiﬁ ed within 1 
h of diagnosis,6 and the patient placed nil by mouth.
Following resuscitation, a focused history and examination 
should ensue. This may determine an aetiology and/
or complications related to AUGIB (Table 1). Features of 
peritonitis and bowel obstruction, which may indicate peptic 
ulcer perforation, are contraindications to endoscopy and 
warrant radiological and surgical assessment. 
2. Risk Assessment
NICE and SIGN advocate a two-step risk assessment 
strategy:6,7
Variceal assessment 
This involves assessing the likelihood of varices prior to 
commencing variceal measures. The assessment is based 
on the presence of established varices, or risk factors for 
portal hypertension, such as established cirrhosis, stigmata 
of chronic liver disease, biochemical and radiological ﬁ ndings. 
Empirical management is discussed below.
Severity assessment
The Blatchford (Figure 2a) and Rockall scores (Figure 2b) 
are validated scoring systems that predict endoscopic and 
clinical outcomes,12,13 and can be used as triaging tools 
for endoscopy. Patients with high risk scores should be 
Peptic ulcer
Erosive 
duodenitis
Malignancy
Mallory-Weiss Tear
Varices
Portal hypertensive 
gastropathy
Vascular ectasia
No cause found
Oesophagitis
Gastritis/Erosions 12%
2%
8%
17%
16%
26%
9%
3%
3%
4%
Table 1 Pointers towards aetiology of UGIB based on history and 
examination ﬁ ndings
History/examination Aetiology
NSAID use, previous ulcer, 
systemic illness
Peptic ulcer disease/
gastroduodenitis
Alcohol excess, chronic 
liver disease, spider naevi, 
jaundice, hepatosplenomegaly, 
encephalopathy, ascites
Varices/portal hypertensive 
gastropathy
Excessive retching and vomiting 
prior to haematemesis
Mallory-Weiss tear
Weight loss, dysphagia Stricture/malignancy
Chronic reﬂ ux, bisphosphonate 
use
Oesophagitis
Previous abdominal aortic 
aneurysm repair
Aorto-enteric ﬁ stula
Chronic kidney disease Vascular ectasia
Recent endoscopic retrograde 
cholangiopancreatography
Post-sphincterotomy bleed
Peritonitis Perforated ulcer
Cachexia/lymphadenopathy Malignancy
Figure 1 Causes of acute 
upper GI bleeding in the UK5
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prioritised for endoscopy, with all cases performed within 24 h 
of admission. Low-risk patients, i.e. Blatchford score of 0–1, 
may be considered for discharge with outpatient endoscopy.8,14 
Recently, the AIMS65 score has been introduced as another 
pre-endoscopic risk assessment tool, comprising Albumin 
(< 3 g/L), INR > 1.5, Mental state alteration, Systolic blood 
pressure < 90, Age > 65.15 Although AIMS65 has not been 
adopted in UK guidelines, it is practical and appears superior 
to pre-endoscopic Rockall and Blatchford scores in predicting 
inpatient mortality, length of stay, and need for intensive care 
admission.16
3. Pre-endoscopic medical management 
Following risk assessment, patients should be referred for 
endoscopy once medically optimised. It is worth emphasising 
that endoscopy is routinely performed with oxygen delivered 
via nasal cannulae. Patients who remain hypoxic despite this 
may beneﬁ t from anaesthetic input for airway intubation if 
endoscopy is urgently indicated. Furthermore, the following 
aspects should be considered:
Coagulopathy
Coagulopathy should be identiﬁ ed and corrected prior to 
endoscopy (Table 2). ESGE recommends the INR be corrected 
to < 2.5 prior to performing endoscopy.8 Patients with AUGIB 
while on novel oral anticoagulants, should be discussed with 
local haematologists; there are no data to support routine 
administration of fresh frozen plasma.
Proton pump inhibitors (PPI)
The guidance on whether to administer PPI therapy prior to 
endoscopy is conﬂ icting. A 2010 Cochrane meta-analysis of 
six randomised controlled trials (RCTs) (n = 2223) showed 
that PPIs before endoscopy signiﬁ cantly reduced stigmata of 
recent haemorrhage at index endoscopy (37.2% vs 46.5%; 
OR 0.67, 95% CI 0.54–0.84) and the need for endotherapy 
(8.6% vs 11.7%; OR 0.68, 95% CI 0.50–0.93), without 
affecting rates of rebleeding, surgery, or mortality.17 As 
this approach may mask targets for therapy, NICE and BSG 
do not recommend routine PPI administration.6,7 However, 
Figure 2a Blatchford Score13 Figure 2b Rockall score.12 *Denotes components of pre-
endoscopic Rockall Score
Table 2 NICE guidelines for correction of coagulopathy during 
AUGIB6
 Coagulopathy Threshold Management
Platelets <50 x109/L
Platelet 
transfusion
INR >1.5
FFP 
PCC (if on 
warfarin)
aPTTr >1.5 FFP
Fibrinogen <1.5g/L
FFP
Cryoprecipitate (if 
low despite FFP)
INR, International Normalised Ratio; aPTTr, activated partial 
thromboplastin time ratio; PCC, prothrombin complex concentrate; 
FFP, fresh frozen plasma.
following cost-effectiveness analyses, ESGE recommends 
pre-endoscopic PPI infusion.8 
Variceal measures (terlipressin and antibiotics)
Patients with suspected variceal haemorrhage should be 
considered for prompt administration of variceal measures, 
terlipressin (or an alternative) and antibiotics.18 Terlipressin, 
a vasopressin analogue, increases systemic vascular 
resistance, reduces cardiac output, and reduces portal 
pressures by approximately 20%.19 The dose in variceal 
haemorrhage is 2 mg four times a day. A meta-analysis of 
seven RCTs (n = 443) showed an overall efﬁ cacy of achieving 
haemostasis with terlipressin in 75–80%, and signiﬁ cant 
reductions in mortality of 34% (95% CI 12%–51%).20 
Trials comparing terlipressin to somatostatin have shown 
no differences in mortality or rebleeding.19,21 Physicians 
should be aware of contraindications to terlipressin 
which include arterial disease, hyponatraemia, myocardial 
ischaemia, severe cardiac failure and prolonged QTc interval. 
Somatostatin or octreotide may be considered for patients 
with contraindications.18,21 
Bacterial infections are common in cirrhotic patients with 
AUGIB. Twenty percent of patients have infections within 48 
h, increasing to 36% after 7 days.22 Infection is associated 
with signiﬁ cantly increased rebleeding risk (43.5% vs 9.8%) 
and mortality (47.8% vs 14.6%).22 It remains unclear whether 
bleeding or infection constitutes the primary event. A meta-
analysis of 12 RCTs associated Gram-negative antibiotic 
prophylaxis with reduced mortality (RR 0.79, 95% CI 0.63–
0.98) and rebleeding (RR 0.53, 95% CI 0.38–0.74).23 As 
such, antibiotic prophylaxis has been adopted as a standard 
of care in cirrhotic patients with AUGIB.6,7,8,18
Prokinetics
A frequent question relates to pre-endoscopic prokinetic 
use in AUGIB. A meta-analysis of eight studies (n = 598) 
on the use of erythromycin infusion prior to endoscopy in 
AUGIB found signiﬁ cant improvements in adequate mucosal 
visualisation (OR 4.1, 95% CI 2.0–8.5), reductions in the 
need for second-look endoscopy (15.1% vs 25.7%, OR 0.51; 
95% CI: 0.34–0.77) and length of stay (mean difference 
-1.75; 95% CI: -2.43 to -1.06).24 ESGE recommends a 250 mg 
erythromycin infusion 30–120 min pre-endoscopy in patients 
with clinically severe/ongoing AUGIB.8 There is no evidence 
to support the use of metoclopramide.
Tranexamic acid
The role of tranexamic acid in AUGIB is unclear and has 
not been recommended in guidelines. A Cochrane meta-
analysis showed a reduction in mortality (RR 0.61, 95% 
CI: 0.42–0.89),25 but the authors considered the studies 
to be insufﬁ ciently powered and of poor quality, with loss 
of beneﬁ t after adjusting for bias. Currently, the HALT-IT 
trial is open for recruitment and aims to clarify the efﬁ cacy 
of tranexamic acid.26 HALT-IT is a pragmatic, double-blind, 
placebo-controlled trial comparing 24 h tranexamic acid 
infusion with placebo, aiming to recruit 8,000 patients 
by November 2017.26 Clinicians should consider liaising 
with their clinical research departments to facilitate trial 
recruitment at the point of presentation. 
Endoscopic management
Endoscopy should be carried out within 24 h of 
presentation.2,6 Endoscopy at an early stage enables the 
determination of the cause of bleeding, prognosis and 
therapeutic interventions to stop bleeding. The management 
of bleeding lesions varies according to whether it is from a 
variceal or non-variceal source. 
1. NVUGIB 
A peptic ulcer may present with high risk stigmata. These 
are: (i) active bleeding, (ii) a non-bleeding visible vessel, 
(iii) adherent clot. Endoscopic haemostasis of such lesions 
has been shown to reduce mortality, rebleeding risk and 
the need for surgery.7,27,28 Endoscopic therapies for NVUGIB 
comprise injection therapy, thermal treatments, mechanical 
adjuncts and spray therapy.
Injection therapy
Injection of adrenaline into and around the point of 
bleeding will reduce the rate of rebleeding.29 However, it 
is recommended that adrenaline injection is accompanied 
by another method of haemostasis.6,7,27 A meta-analysis 
of 16 studies comparing adrenaline monotherapy with 
dual therapy (adrenaline with an additional haemostatic 
technique) showed that dual therapy was superior in 
reducing rebleeding (10.6% vs 18.4%, OR 0.53, 95% CI 
0.40–0.69), emergency surgery (7.6% vs 11.3%, OR 0.64, 
95% CI 0.46–0.90), and mortality (2.6% vs 5.1%, OR 0.51, 
95% CI 0.31–0.84).30
Thermal treatment
There are two types of thermal haemostasis in endoscopy: 
contact and non-contact. Contact treatments involve applying 
pressure and heat via a heater probe using monopolar 
diathermy; the aim of this is to compress and seal a bleeding 
lesion. The probe is applied until the treated areas are 
black and depressed.7 Non-contact thermal haemostasis 
includes argon plasma coagulation, which is sufﬁ cient for 
the treatment for superﬁ cial angiodysplastic lesions.31
Mechanical treatment
The most common mechanical haemostasis device is the 
endoclip or haemoclip. These are stainless steel clips 
which are passed through the endoscope and deployed to 
the bleeding lesion. When applied correctly, clips provide 
mechanical compression to the bleeding vessel, resulting 
in haemostasis. In a meta-analysis,32 clip application was 
shown to be superior to injection therapy in achieving 
deﬁ nitive haemostasis (86.5% vs 75.4%, RR 1.14, 95% 
CI: 1.00–1.30), but comparable to thermal treatment. Clip 
deployment has the additional advantage of identifying the 
bleeding lesion at interventional radiology (see below).
Haemostatic agents
Recently, topical haemostatic agents such as Hemospray 
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following cost-effectiveness analyses, ESGE recommends 
pre-endoscopic PPI infusion.8 
Variceal measures (terlipressin and antibiotics)
Patients with suspected variceal haemorrhage should be 
considered for prompt administration of variceal measures, 
terlipressin (or an alternative) and antibiotics.18 Terlipressin, 
a vasopressin analogue, increases systemic vascular 
resistance, reduces cardiac output, and reduces portal 
pressures by approximately 20%.19 The dose in variceal 
haemorrhage is 2 mg four times a day. A meta-analysis of 
seven RCTs (n = 443) showed an overall efﬁ cacy of achieving 
haemostasis with terlipressin in 75–80%, and signiﬁ cant 
reductions in mortality of 34% (95% CI 12%–51%).20 
Trials comparing terlipressin to somatostatin have shown 
no differences in mortality or rebleeding.19,21 Physicians 
should be aware of contraindications to terlipressin 
which include arterial disease, hyponatraemia, myocardial 
ischaemia, severe cardiac failure and prolonged QTc interval. 
Somatostatin or octreotide may be considered for patients 
with contraindications.18,21 
Bacterial infections are common in cirrhotic patients with 
AUGIB. Twenty percent of patients have infections within 48 
h, increasing to 36% after 7 days.22 Infection is associated 
with signiﬁ cantly increased rebleeding risk (43.5% vs 9.8%) 
and mortality (47.8% vs 14.6%).22 It remains unclear whether 
bleeding or infection constitutes the primary event. A meta-
analysis of 12 RCTs associated Gram-negative antibiotic 
prophylaxis with reduced mortality (RR 0.79, 95% CI 0.63–
0.98) and rebleeding (RR 0.53, 95% CI 0.38–0.74).23 As 
such, antibiotic prophylaxis has been adopted as a standard 
of care in cirrhotic patients with AUGIB.6,7,8,18
Prokinetics
A frequent question relates to pre-endoscopic prokinetic 
use in AUGIB. A meta-analysis of eight studies (n = 598) 
on the use of erythromycin infusion prior to endoscopy in 
AUGIB found signiﬁ cant improvements in adequate mucosal 
visualisation (OR 4.1, 95% CI 2.0–8.5), reductions in the 
need for second-look endoscopy (15.1% vs 25.7%, OR 0.51; 
95% CI: 0.34–0.77) and length of stay (mean difference 
-1.75; 95% CI: -2.43 to -1.06).24 ESGE recommends a 250 mg 
erythromycin infusion 30–120 min pre-endoscopy in patients 
with clinically severe/ongoing AUGIB.8 There is no evidence 
to support the use of metoclopramide.
Tranexamic acid
The role of tranexamic acid in AUGIB is unclear and has 
not been recommended in guidelines. A Cochrane meta-
analysis showed a reduction in mortality (RR 0.61, 95% 
CI: 0.42–0.89),25 but the authors considered the studies 
to be insufﬁ ciently powered and of poor quality, with loss 
of beneﬁ t after adjusting for bias. Currently, the HALT-IT 
trial is open for recruitment and aims to clarify the efﬁ cacy 
of tranexamic acid.26 HALT-IT is a pragmatic, double-blind, 
placebo-controlled trial comparing 24 h tranexamic acid 
infusion with placebo, aiming to recruit 8,000 patients 
by November 2017.26 Clinicians should consider liaising 
with their clinical research departments to facilitate trial 
recruitment at the point of presentation. 
Endoscopic management
Endoscopy should be carried out within 24 h of 
presentation.2,6 Endoscopy at an early stage enables the 
determination of the cause of bleeding, prognosis and 
therapeutic interventions to stop bleeding. The management 
of bleeding lesions varies according to whether it is from a 
variceal or non-variceal source. 
1. NVUGIB 
A peptic ulcer may present with high risk stigmata. These 
are: (i) active bleeding, (ii) a non-bleeding visible vessel, 
(iii) adherent clot. Endoscopic haemostasis of such lesions 
has been shown to reduce mortality, rebleeding risk and 
the need for surgery.7,27,28 Endoscopic therapies for NVUGIB 
comprise injection therapy, thermal treatments, mechanical 
adjuncts and spray therapy.
Injection therapy
Injection of adrenaline into and around the point of 
bleeding will reduce the rate of rebleeding.29 However, it 
is recommended that adrenaline injection is accompanied 
by another method of haemostasis.6,7,27 A meta-analysis 
of 16 studies comparing adrenaline monotherapy with 
dual therapy (adrenaline with an additional haemostatic 
technique) showed that dual therapy was superior in 
reducing rebleeding (10.6% vs 18.4%, OR 0.53, 95% CI 
0.40–0.69), emergency surgery (7.6% vs 11.3%, OR 0.64, 
95% CI 0.46–0.90), and mortality (2.6% vs 5.1%, OR 0.51, 
95% CI 0.31–0.84).30
Thermal treatment
There are two types of thermal haemostasis in endoscopy: 
contact and non-contact. Contact treatments involve applying 
pressure and heat via a heater probe using monopolar 
diathermy; the aim of this is to compress and seal a bleeding 
lesion. The probe is applied until the treated areas are 
black and depressed.7 Non-contact thermal haemostasis 
includes argon plasma coagulation, which is sufﬁ cient for 
the treatment for superﬁ cial angiodysplastic lesions.31
Mechanical treatment
The most common mechanical haemostasis device is the 
endoclip or haemoclip. These are stainless steel clips 
which are passed through the endoscope and deployed to 
the bleeding lesion. When applied correctly, clips provide 
mechanical compression to the bleeding vessel, resulting 
in haemostasis. In a meta-analysis,32 clip application was 
shown to be superior to injection therapy in achieving 
deﬁ nitive haemostasis (86.5% vs 75.4%, RR 1.14, 95% 
CI: 1.00–1.30), but comparable to thermal treatment. Clip 
deployment has the additional advantage of identifying the 
bleeding lesion at interventional radiology (see below).
Haemostatic agents
Recently, topical haemostatic agents such as Hemospray 
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(Cook Medical) have been released. These agents achieve 
haemostasis by mechanically adhering to a bleeding site, 
resulting in mechanical tamponade, and by activating 
coagulation factors to promote thrombus formation. 
Hemospray is safe, as the powder is not absorbed 
systemically. Hemospray is sprayed via an endoscopically-
directed catheter, and has the ability to cover large areas with 
multiple bleeding points, without the need for precise lesion 
targeting. It is a suitable choice for bleeding lesions such 
as haemorrhagic gastritis, portal hypertensive gastropathy, 
gastric antral vascular ectasia, radiation-induced mucosal 
injury and malignancy-related bleeding.33 As such, Hemospray 
has emerged as a promising alternative treatment for difﬁ cult 
to access bleeding lesions or as an adjunct to combinations 
of injection therapy with thermal or mechanical treatments.34 
2. Variceal 
Varices occur as a result of portal hypertension, which 
leads to increases in portal pressure and development of 
portosystemic shunts. In the upper gastrointestinal tract, 
these occur through the gastro-oesophageal veins, leading 
to varices in the distal oesophagus and upper stomach. 
Endoscopic options for variceal bleeding include band ligation, 
sclerotherapy and Sengstaken tube insertion. Management 
of gastric varices depend on the anatomical subtype (Figure 
3).18,35 The evidence base for endoscopic management of 
gastric varices is much weaker than for oesophageal varices.
Variceal band ligation (VBL)
Although sclerotherapy had historically been the mainstay of 
treatment for bleeding varices,36 this has been superseded 
by VBL for oesophageal varices. A meta-analysis of seven 
randomised trials found VBL to be superior to sclerotherapy 
in reducing rebleeding (OR 0.52, 95% CI 0.37–0.74) and 
mortality (OR 0.67, 95% CI 0.46–0.98).37 VBL should be 
used in conjunction with terlipressin, somatostatin or 
octreotide.18 VBL involves attaching a small plastic tube to 
the end of the endoscope, around which small rubber bands 
are placed. The endoscope is used to suck the varix into the 
tube and a rubber band is deployed to induce strangulation 
and thrombosis of the varix. VBL is also recommended by 
the BSG for the management of type 1 gastro-oesophageal 
varices (GOV-1), which occur in 75% of gastric varices. The 
most common complication of VBL is post-band ulceration, 
the size of which may be reduced by PPI use.38 
Cyanoacrylate and thrombin
Cyanoacrylate, also known as ‘glue’, is a strong adhesive 
with multiple industrial and domestic applications. For type 
2 gastro-oesophageal varices (GOV-2) and isolated gastric 
varices (IGV), cyanoacrylate has been shown to be superior 
to VBL in achieving haemostasis and reducing rebleeding,39,40 
and has been approved by NICE and BSG.6 Recently, 
thrombin injection has been accepted as an alternative to 
cyanoacrylate for gastric varices,18 with haemostasis rates 
of 94% and rebleeding rates of 18%.41 There have been no 
head-to-head trials comparing thrombin to sclerosant therapy.
Balloon tamponade
Balloon tamponade is indicated in failure of haemostasis 
with bleeding oesophageal varices and most types of 
gastric varices (GOV-1, GOV-2, and IGV-1).18 The Sengstaken-
Blakemore tube (SBT) (Figure 4) is the most common device 
for balloon tamponade. It achieves haemostasis in 91.5% of 
cases, with recurrence of bleeding in approximately 50% of 
cases after balloon deﬂ ation.42 It is thus useful as a bridge to 
a more deﬁ nitive procedure (discussed below). Complications 
of SBT occur in 15–20% of patients, and include pressure 
necrosis, misplacement, aspiration pneumonia and 
oesophageal rupture.18 Due to its poor tolerability, patients 
often require heavy sedation and intubation prior to SBT 
Figure 3 Classification of gastric varices.35 GOV-1: oesophageal 
varices extending along lesser curve; GOV-2: oesophageal varices 
extending along fundus; IGV-1: Isolated fundal varices; IGV-2: 
Isolated varices in gastric antrum, body or pylorus
Figure 4 Sengstaken-Blakemore tube
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insertion and hence should be managed in an intensive 
care unit. 
Oesophageal stenting
Lately, there have been data supporting the role of self-
expanding metal stent placement in cases of refractory 
bleeding oesophageal varices.43 Self-expanding metal stents 
have been shown to be superior to SBT in this setting, with a 
recent RCT showing improved treatment success, deﬁ ned as 
survival at day 15 with control of bleeding and without serious 
adverse events (66% vs 20%, p = 0.025).44 Self-expanding 
metal stents can be deployed without radiological guidance 
and can be left in for 14 days (vs 2 days for SBT),18 and have 
been approved by NICE.45
3. Endoscopic Reporting
A good endoscopy report is vital for recording and handover 
purposes. Although quality assurance for diagnostic 
gastroscopy has been outlined,46 quality assurance on 
endoscopy reporting speciﬁ c to AUGIB has not featured 
in national guidelines. A major recommendation from the 
2015 NCEPOD report was for all patients to have a clearly 
documented rebleed plan.2 In 2016, the Joint Advisory Group 
for Gastrointestinal Endoscopy (JAG) implemented AUGIB 
DOPS (Directly Observed Procedural Skills) forms to include 
assessment of endoscopy reporting by endoscopy trainees. 
This included documentation of the following aspects: 
indications, pre-procedural risk scoring, accurate description 
of identified lesion and location, photodocumentation, 
description of rebleeding stigmata and endotherapy, 
complications/difficulties encountered, rebleeding risk, 
speciﬁ c treatments to be initiated, and rebleeding plan.47 
The report should also include instructions on re-initiation 
of feeding and antithrombotic drugs.48
Post-endoscopic management
Following endoscopy, physicians should carefully scrutinise 
the endoscopy report. High risk patients should be escalated 
to a high dependency unit setting. Patients should be 
monitored for rebleeding and medical comorbidity. Rebleeding 
risk should be quantiﬁ ed according to factors outlined on 
the report, such as: adequacy of haemostasis, interventions 
applied (monotherapy vs combination therapy), complete 
Rockall score,12 and Forrest classiﬁ cation of PUD (Figure 5). 
A discussion with the endoscopist should take place if there 
is a lack of clarity. The following evidence-based management 
should be considered depending on the endoscopic ﬁ ndings:
1. NVUGIB
PPI therapy
Increased gastric pH has been linked with improved clot 
stability.50 A landmark placebo-controlled randomised trial 
from Hong Kong showed that continuous omeprazole infusion 
(80 mg intravenous bolus followed by 8 mg/h for 72 h) after 
endotherapy for peptic ulcer was superior to placebo in 
reducing recurrent bleeding, transfusion requirements and 
hospital stay.51 This has since been replicated in a Cochrane 
review,52 and unanimously incorporated into guidelines for 
post-endoscopic management of peptic ulcer bleeding.6–8
Moreover, the efﬁ cacy of PPI may not be restricted to PUD. 
A meta-analysis of 26 trials (n = 4670) comparing PPI to 
placebo after any high-risk non-variceal lesion showed 
reduced rebleeding (OR 0.48; 95% CI 0.40–0.57) and surgery 
(OR 0.61; 95% CI 0.48–0.76) in favour of PPI, but not overall 
mortality.53 More recently, the method of PPI administration 
has been challenged, with meta-analysis data showing non-
inferiority in rebleeding risk with intermittent vs continuous 
regimens (RR 0.72, p = 0.10), or with oral versus intravenous 
formulations (RR 0.92, p = 0.95).54 NICE recommends routine 
administration of PPI to patients with NVUGIB and stigmata 
Figure 5 Forrest classification of PUD with prevalences and post-endotherapy rebleed risks based on data from Guglielmi et al.49 
A) Forrest 3: Clean base, B) Forrest 2c: Flat pigmented spot, C) Forrest 2b: Adherent clot, D) Forrest 2a: Visible vessel, E) Forrest 1b: 
Oozing vessel, F) Forrest 1a: Spurting vessel
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of recent haemorrhage shown at endoscopy,6 but does not 
specify the route, dosage or duration. ESGE recommends for 
patients with peptic ulcers with ﬂ at pigmented spot (Forrest 
IIc) or clean base (Forrest III) to be discharged with once 
daily oral PPI.8
Helicobacter pylori
H. pylori is perhaps the single most important aetiological 
factor in PUD. Although the prevalence of H. pylori appears 
to have fallen since the 1990s,55 infection rates in bleeding 
PUD remain high.56 A 2012 study found a prevalence of 66% 
in uncomplicated duodenal ulcers and 47% of gastric ulcers, 
with an overall prevalence of 66% in bleeding PUD,56 which 
was similar to previous estimates of 71% in bleeding duodenal 
ulcers and 65% in bleeding gastric ulcers.57 However, the 
true prevalence in bleeding PUD may be higher;55 it is widely 
acknowledged that sensitivity of diagnostic tests for H. 
pylori is diminished during AUGIB, with false negative rates 
estimated to be between 25 and 50%.58 
Detection and eradication are important as they lead to 
improved outcomes, and obviate the need for long term PPI.59 
In a Cochrane meta-analysis of patients with H. pylori-related 
bleeding PUD (without NSAID use), H. pylori eradication was 
superior to non-eradication (OR 0.16, 95% CI 0.09–0.30, 
p < 0.00001, NNT = 7) or long-term antisecretory therapy 
(OR 0.14, 95% CI 0.05–0.43; p = 0.0006, NNT = 20) for 
preventing rebleeding.59 Subsequently, AUGIB guidelines have 
called for H. pylori assessment (ideally during endoscopy with 
biopsy methods, urea breath testing or monoclonal stool 
antigen testing).6–8 If positive, H. pylori eradication should be 
commenced at reintroduction of oral feeding,60 as delayed 
treatment can lead to loss of follow-up and poorer compliance. 
Currently, NICE recommends a 7-day twice daily regimen 
consisting of PPI and dual antibiotic therapy (amoxicillin and 
clarithromycin/metronidazole) for eradication,61 although 
evidence exists to support extending the duration to 14 
days,62 and for ﬁ rst-line sequential therapy.63 PPI treatment 
should continue for a total of 4 weeks,7 and discontinued for 
at least 2 weeks before H. pylori reassessment.7 Although 
NICE advocates urease breath testing for reassessment,61 
stool antigen testing 6 weeks after discharge appears to be 
a reasonable alternative.60 Second-line measures should be 
started for eradication failure.61
Transfusions thresholds
Two well-designed RCTs have compared outcomes 
between restrictive and liberal transfusion strategies in 
haemodynamically stable patients with AUGIB.64,65 Villanueva 
et al. demonstrated that a transfusion trigger of 70 g/L vs 90 
g/L haemoglobin was associated with signiﬁ cantly reduced 
6-week mortality (HR 0.55, 95% CI 0.33–0.92), rebleeding 
(HR 0.62, 95% CI 0.43–0.91), adverse events (HR 0.73, 
95% CI: 0.56–0.95) and blood transfusions, without a 
signiﬁ cant difference in 6 week haemoglobin.64 Moreover, the 
authors correlated a liberal approach with increases in portal 
pressures,64 which is implicated in variceal bleeding. The 
TRIGGER trial,65 which was a UK-based pragmatic RCT (n = 
936), showed no signiﬁ cant difference in outcomes between 
the restrictive (80 g/L) and liberal (100 g/L) strategies. Based 
on this, ESGE recommends a restrictive transfusion strategy 
(target haemoglobin between 70 –90 g/L) after haemostasis.8
Iron replacement
Patients are often discharged from hospital with anaemia 
after AUGIB.66 One retrospective study reported a prevalence 
of 80%, with iron supplementation in only 16%.66 Adoption 
of restrictive transfusion strategies may increase rates of 
anaemia at discharge. One RCT (n = 97) assigned patients 
with post-AUGIB anaemia to either placebo, oral iron (200 
mg daily for 3 months) or intravenous iron (a single 1000 
mg infusion).67 Iron replacement was superior to placebo 
in reducing rates of anaemia at 13 weeks (17% vs 70%, 
p < 0.01), with highest efﬁ cacy in the intravenous group.67 
Although iron supplementation is not prescribed in AUGIB 
guidelines this should nonetheless be considered prior to 
discharge.
Antithrombotic therapy
Antithrombotic drugs, e.g. aspirin, thienopyridines and 
anticoagulants, are often stopped during AUGIB and 
not resumed.68 These are often indicated for secondary 
prophylaxis of cardiovascular and thrombotic events. In an 
RCT (n = 156) involving patients with NVUGIB on aspirin, 
discontinuation of aspirin was associated with increased all-
cause mortality at 8 weeks compared to aspirin maintenance 
(10.3% vs 1.3%, p = 0.001).69 Mortality mainly arose due 
to thrombotic events, without a signiﬁ cant difference in 
rebleeding rates.69 This effect does not appear to be limited 
to aspirin; one study has associated discontinuation of 
any antithrombotic therapy following AUGIB with increased 
cardiovascular mortality (RR 4.5, p = 0.03), all-cause 
mortality (RR 3.0, p = 0.003), and cardiovascular events 
(RR 6.1, p = 0.003) over one year of follow-up.68
NICE recommends continuing low-dose aspirin for secondary 
prevention of vascular events in patients with AUGIB after 
haemostasis.6 ESGE recommends immediate resumption of 
aspirin following index endoscopy if the risk of rebleeding 
is low (e. g. Forrest IIc and Forrest III lesions).8 In patients 
with high risk peptic ulcer (Forrest 1a to Forrest 2b lesions), 
ESGE recommends early reintroduction of aspirin by day 
3 after endotherapy.8 For thienopyridines/anticoagulants, 
indications should be reviewed, with specialist input if 
necessary, and resumed if there are compelling indications 
to reduce cardiovascular risk.6
Rebleeding (non-variceal)
Rebleeding occurs in approximately 13–23% of cases.2,5 
NICE recommends offering repeat endoscopy to patients who 
rebleed, or if there is doubt regarding adequate haemostasis 
at index endoscopy.6 If there is a failure of endoscopic 
haemostasis, unstable patients should be considered for 
interventional radiology or surgery. In the 12% of patients 
where there is no cause apparent on index endoscopy,5 repeat 
oesophagogastroduodenoscopy should be considered in the 
event of rebleeding,6 with a view to colonic and small bowel 
investigations if haemorrhage persists. 
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CT angiography and transcatheter arterial embolisation 
CT angiography is a non-invasive assessment tool for obscure 
gastrointestinal bleeding, with a sensitivity of 86% and 
speciﬁ city of 95%.70 It can also detect vascular malformations, 
neoplasms, small bowel and lower gastrointestinal bleeding 
sources, in addition to providing evidence of stigmata of recent 
haemorrhage, such as extravasated blood in the bowel lumen. 
However, CT angiography requires the rate of haemorrhage 
to be at least 0.5 ml/min to reliably demonstrate luminal 
extravasation of contrast at the bleeding source.71 If conﬁ rmed, 
the patient may proceed to catheter angiography (Figure 6). This 
is performed by interventional radiologists, who obtain access 
via the femoral artery and perform selective catheterisation 
of mesenteric vessels to prepare for transcatheter arterial 
embolisation (TAE). The coeliac artery and its gastric and 
gastroduodenal branches are often interrogated ﬁ rst, as most 
peptic ulcers receive blood supply from the gastroduodenal 
artery.72 In the absence of a bleeding source, the superior and 
inferior mesenteric arteries may be evaluated. If a bleeding 
source is identiﬁ ed, TAE is performed.72 Although metal coils 
are the embolic agent of choice, additional options include 
glue, polyvinyl alcohol particles, and Gelfoam (absorbable 
compressed sponge).72 Potential complications of TAE include 
transient abdominal pain, bowel ischaemia, arterial injury and 
contrast nephropathy.72
Although salvage surgery has been traditionally the default 
option for patients with uncontrolled haemorrhage, the 
2007 UK audit showed higher mortality after surgery than 
TAE (29% vs 10%).73 The audit showed that patients who 
rebled were more likely to undergo surgery (2.2%) than TAE 
(1.5%), with surgical modalities consisting of: ulcer under-
run (69%), ulcer excision (3%), ulcer excision with vagotomy/
pyloroplasty (2%), partial gastrectomy (9%), and other (16%). 
At the time, less than 10% of hospitals had access to 24 h 
interventional radiology. No prospective studies or RCTs have 
compared surgery to TAE. From the 2015 NCEPOD audit,2 
only 27% of hospitals could offer 24 h on-site embolisation. 
Unfortunately, the choice of therapy will remain dictated by 
service availability. 
Follow-up
Most patients do not receive outpatient follow-up after 
NVUGIB. Follow-up endoscopy for gastric ulcers after 6–8 
weeks is recommended,61 depending on the size of the 
lesion, as gastric ulcers may harbour malignant change. 
Colonoscopic or small bowel assessment may be warranted 
in recurrent or occult bleeding. It is reasonable to arrange 
community follow-up monitoring of symptoms, biochemistry, 
and review of medications. 
2. Variceal 
Terlipressin
The pre-endoscopic role of terlipressin has been discussed 
above. The optimal duration of terlipressin has only been 
assessed in one trial,75 in which 509 patients with variceal 
haemorrhage who had been stabilised with sclerotherapy 
and 48 h of terlipressin were randomised to an additional 5 
days of terlipressin or placebo, before repeating sclerotherapy 
at day 7. Maintenance of terlipressin was associated with 
reduced 28-day rebleeding rates (9.7% vs 21.8%, p = 0.001), 
but without differences in mortality. Although terlipressin has 
a 72 h manufacturer’s licence, NICE recommends continuing 
until certainty of haemostasis or after 5 days, unless other 
indications exist for its use, such as hepatorenal syndrome.6 
Non-selective beta blockers
After the ﬁ rst variceal haemorrhage, the risk of rebleeding 
is 15–30% within the subsequent 6 weeks.76 Currently, 
the mainstay of pharmacological secondary prophylaxis is 
with non-selective beta-blockers, such as propranolol or 
carvedilol.18 Propranolol reduces portal pressures through 
splanchnic vasoconstriction and reduced cardiac output. A 
meta-analysis of 12 RCTs (11 with propranolol) for secondary 
prophylaxis of variceal bleeding showed that, over two years, 
use of non-selective beta-blockers was associated with 
freedom from variceal rebleeding (20% mean difference, 95% 
CI: 11–28%, p < 0.001), and increased survival (5.4% mean 
difference, 95% CI: 0%–11%, p < 0.05, RR 1.27).77 Carvedilol, 
which has vasodilator properties due to α1-receptor blockade, 
has been shown in haemodynamic studies to reduce portal 
pressures more effectively than propranolol.78 However, there 
has been no randomised trial comparing carvedilol with 
carvedilol + VBL. As such, recent BSG guidelines recommend 
use of propranolol or nadolol for secondary prevention of 
variceal bleeding, with carvedilol as an alternative.18 The 
addition of isosorbide mononitrate to non-selective beta-
blockers does not appear to affect rebleeding or mortality,79 
and has not been recommended in guidelines.
Variceal band ligation (VBL)
Patients should be scheduled for elective repeat endoscopy 
2–4 weeks after variceal haemorrhage until eradication of 
varices,18 although this is controversial.80 One RCT of monthly 
Figure 6 Arterial embolisation 
in a patient with rebleeding 
from a duodenal ulcer at 
endoscopy despite injection 
and clip therapy.74 
A: Angiography, guided by clip 
position (arrow), without 
active extravasation; B: 
Result after coil embolisation 
of the distal and proximal 
gastroduodenal artery
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vs biweekly VBL found an increased risk of post-VBL ulcers in 
the biweekly group (57% vs 11%, p < 0.001) without signiﬁ cant 
differences in mortality.81 After successful eradication of 
varices, patients should be booked for endoscopy at 3 
months, then 6-monthly thereafter.18 Recurrent varices should 
be treated with VBL until eradication. 
Transfusion thresholds
The rationale for a restrictive transfusion strategy in 
variceal bleeding has been covered in the NVUGIB section. 
BSG recommends a transfusion threshold of 70–80 
g/L in haemodynamically stable patients with variceal 
haemorrhage.18
Transjugular intrahepatic portosystemic shunt (TIPSS) and 
rebleeding
Patients who rebleed should be considered for urgent repeat 
endoscopy and VBL. If rebleeding is difﬁ cult to control, SBT 
or self-expanding metal stent can be attempted until salvage 
TIPSS or surgical shunt surgery is performed.18 The aim of 
TIPSS is to rapidly reduce portal pressures by creating a 
portosystemic shunt across the liver parenchyma (Figure 7). 
TIPSS is performed by specialist interventional radiologists, 
and has been shown to be superior to VBL for preventing 
rebleeding (19.0% vs 43.8%, OR 0.32, 95% CI 0.24–0.43, 
p < 0.00001), but with increased rate of post-procedural 
encephalopathy (OR 2.21, 95% CI 1.61–3.03, p < 0.00001).82 
Contraindications to TIPSS are summarised in Table 3.83 For 
those with anatomical contraindications, shunt surgery may 
be considered. 
The role of TIPSS may not be conﬁ ned to salvage treatment. 
There is RCT evidence,85 recently endorsed by BSG,18 to 
support the role for early TIPSS in select patients (Child B 
and Child C cirrhosis with score < 14) within 72 h of a variceal 
bleed. As such, referral to a specialist liver unit for TIPSS may 
be appropriate even after index presentation with variceal 
Figure 7 TIPSS procedure.84
A: Insertion of a catheter-
guided needle passed from 
the internal jugular to right 
hepatic vein to puncture the 
portal vein. B: Insertion of 
guide-wire into the portal 
system. C: Dilatation of 
hepatic parenchyma between 
the portal vein and hepatic 
vein. D: Stent placement in 
the newly formed tract
 Table 3 Contraind ications to TIPSS83 
Absolute Relative
Primary prevention Hepatic encephalopathy
Severe pulmonary 
hypertension (pulmonary 
arterial pressure >45mmHg)
Hepatoma
Polycystic liver disease Hepatic vein/portal vein 
thrombosis
Uncontrolled systemic 
infection
Severe uncorrectable 
coagulopathy
Unrelieved biliary obstruction Moderate pulmonary 
hypertension
Severe congestive cardiac 
failure
Advanced cirrhosis (Child C)
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bleeding. Units that do not offer a TIPSS service should 
identify a specialist centre which offers a 24 h emergency 
TIPSS service and have appropriate arrangements for safe 
transfer of patients in place.18 
Follow-up
All patients with cirrhosis should receive hepatology follow-
up after discharge. This includes hepatocellular carcinoma 
surveillance (6-monthly α-fetoprotein and ultrasound 
assessment), monitoring and managing liver disease and 
its complications, consideration of transplant assessment, 
and addressing variceal surveillance.
Table 4 Key ﬁ ndings and recommendations from NCEPOD 20152
NCEPOD Findings NCEPOD Recommendation
23% of patients suffered a rebleed.
42% who had an endoscopy for NVUGIB and 32% for variceal 
bleed had no rebleed plan.
Care pathways for all GI bleeds should include, as a minimum, 
risk assessment, escalation of care, transfusion documentation, 
core procedural documentation, network arrangements and 
rebleed plans. The pathway needs to be clearly documented.
All patients with a GI bleed must have a clearly documented 
rebleed plan agreed at the time of each diagnostic or therapeutic 
intervention.
24% died overall whilst 38% died who developed a GI bleed whilst 
already in hospital.
GI bleeding was the cause of death in 36% and due to 
complications in 49%.
8% should have had escalation to critical care but did not
Unstable patients should have anaesthetic and/or critical care 
support.
All deaths from major GI bleeds within 30 days of admission 
should undergo combined multidisciplinary peer review to identify 
remediable factors in patient care.
64% of patients with AUGIB did not have any risk assessment 
score calculated.
GI bleed specialists need to develop risk stratification methods 
relevant to all GI bleeding.
6% should have had an interventional radiology procedure but did 
not.
32% of hospitals to which AUGIB patients are admitted do not 
have a 24/7 endoscopy service.
73% of hospitals could not provide 24/7 embolisation of GI 
bleeding on-site.  45% had a formal network to combat this.
51% of hospitals had formal network arrangements for TIPSS. 
Patients with any AUGIB should only be admitted to hospitals with 
24/7 access to on-site endoscopy, interventional radiology 
(on-site or covered by a formal network), on-site GI bleed surgery, 
on-site critical care and anaesthesia.
35% of patients waited longer than 24 hours for an OGD.  
In 16% of cases the reviewers felt that the first consultant review 
was not sufficiently prompt for the patient’s condition. 
All patients who present with major AUGIB should be discussed 
with the duty consultant responsible for major GI bleeds, within 
one hour of the diagnosis of a major bleed.
The ongoing management of care for patients with a major bleed 
should rest with, and be directed by the named consultant 
responsible for GI bleeds; to ensure timely investigation and 
treatment.
All patients with a GI bleed and haemodynamic instability should 
have 24/7 access to an OGD within two hours of optimal 
resuscitation.
Important basic investigations were omitted in 20% admitted with 
AUGIB and 33% of inpatients.
Of the 18% of patients who had complications, these could have 
been avoided with improved care. 
The NICE Clinical Guideline (CG141) for AUGIB should be 
adhered to.
25% of hospitals to which patients with a GI bleed were admitted 
were not JAG accredited. 
All hospitals which admit patients AUGIB should have their 
endoscopy units accredited by JAG
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